Evogene LTD. (EVGN) — 6-K Filings

All 6-K filings from Evogene LTD.. Browse 40 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (40)

6-K Filing — Dec 30, 2025
Evogene Ltd. Reports Q3 2025 Financial Results — Nov 20, 2025 Risk: low
Evogene Ltd. announced its financial results for the third quarter ended September 30, 2025, on November 20, 2025. The company filed a Form 6-K report with the
Evogene Ltd. Files 6-K for H1 2025 Results — Sep 30, 2025 Risk: low
Evogene Ltd. filed a Form 6-K on September 30, 2025, reporting its results of operations for the six months ended June 30, 2025. The filing is for a foreign pri
Evogene Ltd. Files September 2025 6-K Report — Sep 10, 2025 Risk: low
Evogene Ltd. filed a Form 6-K on September 10, 2025, reporting for the month of September 2025. The filing is a report of a foreign private issuer and includes
Evogene Ltd. Reports Q2 2025 Financial Results — Aug 19, 2025 Risk: low
Evogene Ltd. announced its financial results for the second quarter ended June 30, 2025, on August 19, 2025. The company filed a Form 6-K report with the SEC to
Evogene Shareholders Approve All Proposals at Annual Meeting — Aug 18, 2025 Risk: low
Evogene Ltd. announced on August 18, 2025, that its shareholders approved all proposals at the annual general meeting. This meeting, which was adjourned for one
Evogene Annual Meeting Adjourned Due to Lack of Quorum — Aug 11, 2025 Risk: low
Evogene Ltd. held its Annual General Meeting of Shareholders on August 11, 2025, but it was adjourned for one week due to a lack of quorum. The meeting will now
Evogene Ltd. Files Proxy Card for August 11 AGM — Jul 17, 2025 Risk: low
Evogene Ltd. filed a supplemental submission of a proxy card for its Annual General Meeting of Shareholders, scheduled for August 11, 2025. This filing follows
Evogene's Lavie Bio Sells Most Operations to ICL — Jul 8, 2025 Risk: medium
On July 8, 2025, Evogene Ltd. announced that its subsidiary, Lavie Bio Ltd., completed a transaction with Dead Sea Works Ltd., an affiliate of ICL Group Ltd. (I
Evogene Ltd. Announces Annual Shareholder Meeting Date — Jun 17, 2025 Risk: low
Evogene Ltd. has filed a Form 6-K on June 17, 2025, to announce its Annual General Meeting of Shareholders. The meeting is scheduled for August 11, 2025, at 3:0
Evogene Subsidiary Biomica CEO Steps Down Due to Medical Reasons — Jun 5, 2025 Risk: medium
Evogene Ltd. announced changes in its subsidiary Biomica Ltd.'s management on June 5, 2025. Dr. Elran Haber is stepping down as CEO of Biomica due to an unexpec
Evogene Ltd. Reports Q1 2025 Financial Results — May 21, 2025 Risk: low
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2025, on May 21, 2025. The company, headquartered in Rehovot, Israel, is a fo
Evogene Sells Lavie Bio Assets to ICL for $15.25M — Apr 21, 2025 Risk: medium
On April 21, 2025, Evogene Ltd. announced the sale of most of its subsidiary Lavie Bio Ltd.'s activities to Dead Sea Works Ltd., an affiliate of ICL Group Ltd.,
Evogene Ltd. Board Chair Steps Down — Mar 6, 2025 Risk: low
Evogene Ltd. announced on March 6, 2025, that Sarit Firon has stepped down as Chairperson of the Board. The company filed a Form 6-K to report this change in it
Evogene Ltd. Shareholders Approve Key Proposal — Feb 12, 2025 Risk: low
Evogene Ltd. announced on February 12, 2025, that its shareholders approved a proposal at a special general meeting. This meeting was originally scheduled for a
Evogene Ltd. Meeting Adjourned Due to Lack of Quorum — Feb 5, 2025 Risk: low
Evogene Ltd. held a Special General Meeting of Shareholders on February 5, 2025, which was adjourned for one week due to a lack of quorum. The meeting will now
Evogene Ltd. Announces Executive Departure Amid Restructuring — Jan 15, 2025 Risk: low
Evogene Ltd. announced that Eyal Ronen, Executive Vice President of Business Development, will be leaving the company effective March 4, 2025, as part of an org
Evogene Ltd. Schedules Special Shareholder Meeting for Feb 5, 2025 — Dec 30, 2024 Risk: low
Evogene Ltd. has announced a special general meeting of shareholders scheduled for February 5, 2025, at 3:00 p.m. Israel time. The meeting will be held at Evoge
Evogene Subsidiary Lavie Bio's Licensing Deal Terminated by Corteva — Nov 27, 2024 Risk: medium
On November 27, 2024, Evogene Ltd. announced that its subsidiary, Lavie Bio Ltd., received a notice of termination from Corteva Agriscience LLC regarding a lice
Evogene Ltd. Reports Q3 2024 Financial Results — Nov 21, 2024 Risk: low
Evogene Ltd. announced its financial results for the third quarter ended September 30, 2024, on November 21, 2024. The company, which operates in the agricultur
Evogene Ltd. CTO Mark Kapel to Depart — Sep 17, 2024 Risk: low
Evogene Ltd. announced on September 17, 2024, that Chief Technology Officer Mark Kapel will leave the company effective October 31, 2024, as part of an organiza
Evogene Ltd. Files 6-K with Q2 Financials — Sep 16, 2024 Risk: low
Evogene Ltd. filed a Form 6-K on September 16, 2024, to furnish unaudited condensed consolidated financial statements for the period ending June 30, 2024. The f
Evogene Ltd. Raises Capital Through Share Offering — Aug 23, 2024 Risk: medium
On August 23, 2024, Evogene Ltd. entered into a securities purchase agreement to issue and sell 265,000 ordinary shares to an institutional investor in a regist
Evogene Ltd. Reports Q2 2024 Financial Results — Aug 22, 2024 Risk: low
Evogene Ltd. announced its financial results for the second quarter ended June 30, 2024, on August 22, 2024. The company is a foreign private issuer filing a Fo
Evogene Regains Nasdaq Minimum Bid Price Compliance — Aug 12, 2024 Risk: low
Evogene Ltd. announced on August 8, 2024, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per s
Evogene Ltd. Announces 1-for-10 Reverse Share Split — Jul 23, 2024 Risk: medium
Evogene Ltd. announced on July 23, 2024, that it will implement a 1-for-10 reverse share split. This action will consolidate every ten ordinary shares into one,
Evogene Subsidiary Casterra Secures $440K Order — Jun 25, 2024 Risk: low
Evogene Ltd. announced on June 25, 2024, that its subsidiary, Casterra AG Ltd., received an additional purchase order worth approximately $440,000 from an exist
Evogene Ltd. CPO Nir Arbel to Step Down — Jun 20, 2024 Risk: low
Evogene Ltd. announced that Nir Arbel, the Chief Product Officer, will step down from his position on August 15, 2024, due to relocation. The company is current
Evogene Shareholders Approve Proposals, Reject CEO Stock Options — Jun 17, 2024 Risk: low
Evogene Ltd. held its annual general meeting of shareholders on June 13, 2024, where all proposals were approved, except for the resolution regarding the grant
Evogene Annual Meeting Adjourned Due to Lack of Quorum — Jun 6, 2024 Risk: low
Evogene Ltd. held its Annual General Meeting of Shareholders on June 6, 2024, but it was adjourned for one week due to a lack of quorum. The meeting will now re
Evogene Ltd. Files May 2024 6-K Report — May 29, 2024 Risk: low
Evogene Ltd. filed a Form 6-K on May 29, 2024, for the month of May 2024. The filing is a report of a foreign private issuer and includes Exhibit 99.1. Evogene
Evogene Ltd. Reports Q1 2024 Financial Results — May 23, 2024 Risk: low
Evogene Ltd. announced its financial results for the first quarter ended March 31, 2024, on May 23, 2024. The company filed a Form 6-K report with the SEC to fu
Evogene Ltd. Schedules 2024 Annual Shareholder Meeting — Apr 30, 2024 Risk: low
Evogene Ltd. announced its 2024 annual general meeting of shareholders will be held on Thursday, June 6, 2024, at 3:00 p.m. Israel time at its offices. The comp
Evogene Launches Finally Foods for Plant-Based Protein — Apr 2, 2024 Risk: medium
Evogene Ltd. announced on April 2, 2024, the establishment of Finally Foods Ltd., a new company specializing in plant-based protein production for the food indu
Evogene Ltd. Receives Nasdaq Letter — Mar 20, 2024 Risk: medium
On March 20, 2024, Evogene Ltd. announced it received a letter from the Nasdaq Stock Market LLC. The filing does not specify the content or implications of this
Evogene Ltd. Reports Q4 and FY 2023 Financial Results — Mar 7, 2024 Risk: low
Evogene Ltd. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023, on March 7, 2024. The company, incorporated in Isra
Evogene Subsidiary Ag Plenus Appoints Dr. Dan Jacob Gelvan as CEO — Feb 22, 2024 Risk: low
Evogene Ltd. announced on February 22, 2024, changes in the management of its subsidiary, Ag Plenus Ltd. Dr. Dan Jacob Gelvan will be appointed as the new Chief
Evogene Subsidiary Ag Plenus Partners with Bayer for Weed Control — Feb 21, 2024 Risk: low
Evogene Ltd. announced on February 21, 2024, that its subsidiary, Ag Plenus Ltd., has entered into a Licensing and Collaboration Agreement with Bayer AG. This a
Evogene's Biomica Completes Phase I Enrollment for Cancer Drug BMC128 — Jan 17, 2024
Evogene Ltd.'s subsidiary, Biomica Ltd., announced on January 17, 2024, that it successfully completed Phase I trial enrollment for its microbiome-based immuno-
Evogene Files Investor Presentation, CEO Haviv to Present — Jan 9, 2024
Evogene Ltd. filed a 6-K on January 9, 2024, to include an investor presentation dated January 10, 2024. This presentation, led by President & CEO Ofer Haviv, l

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX